Search Results - "Sartor, O.A" :: Katalog Arama

1
Cabozantinib (XL184) At 40 Mg in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC): Results of a Phase 2 Non-Randomized Expansion Cohort (NRE) by de Bono, J.S., Smith, M.R., Rathkopf, D., Corn, P.G., Mukherji, D., Harzstark, A.L., Sartor, O.A., Smith, D.C., Tunariu, N., Sweeney, C.

Published in Annals of oncology (01-09-2012)

Get full text

Journal Article
QR Code
Save to List

Saved in:
2
51 RADIOLOGIC PROGRESSION PREDICTS OVERALL SURVIVAL IN PATIENTS (PTS) WITH ANDROGEN INDEPENDENT PROSTATE CANCER (AIPC) WHO RECEIVED FIRST LINE DOCETAXEL; AN ANALYSIS FROM THE SPARC TRIAL by Witjes, J.A, Petrylak, D, Sartor, O.A, Noursalehi, M, Sternberg, N, Wirth, M, Billiet, I, Petrone, M.E, McKeam, T.J, George, M

Published in European urology supplements : official journal of the European Association of Urology (01-03-2009)

Get full text

Journal Article
QR Code
Save to List

Saved in:
3
SATRAPLATIN (S) INCREASES PROGRESSION-FREE SURVIVAL (PFS) AND DELAYS PAIN PROGRESSION IN PATIENTS (PTS) WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) THAT HAVE PROGRESSED AFTER PRIOR DOCETAXEL by Sternberg, N, Sartor, O.A, Petrylak, D.P, Witjes, F, Bodrogi, I, Harper, P, James, N, Demkov, T, Eymard, J-C, Wirth, M

Published in European urology supplements : official journal of the European Association of Urology (2008)

Get full text

Journal Article
QR Code
Save to List

Saved in: